PTEN and breast carcinoma: Another clue that PARP1 inhibition might be beneficial in other breast cancer subtypes relates to its relationship with phosphatase and tensin homolog (PTEN), a phosphatase that contributes to the regulation of cell cycle progression, cell proliferation and DNA repair.